Trial Profile
Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary)
- Indications Cancer
- Focus Diagnostic use
- 11 Jul 2018 Status changed from suspended to discontinued.
- 14 Dec 2017 Planned End Date changed from 31 Aug 2018 to 31 Oct 2018.
- 14 Dec 2017 Planned primary completion date changed from 29 Jun 2018 to 31 Oct 2018.